GERM-LINE EXCLUSION OF A SINGLE P53 ALLELE BY PREMATURE TERMINATION OF TRANSLATION IN A LI-FRAUMENI SYNDROME FAMILY

被引:0
|
作者
STOLZENBERG, MC
BRUGIERES, L
GARDES, M
DESSARPSFREICHEY, F
CHOMPRET, A
BRESSAC, B
LENOIR, G
BONAITIPELLIE, C
LEMERLE, J
FEUNTEUN, J
机构
[1] INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE
[2] INST GUSTAVE ROUSSY,DEPT PEDIAT ONCOL,F-94805 VILLEJUIF,FRANCE
[3] INSERM,U155,UNITE RECH EPIDEMIOL GENET,F-75016 PARIS,FRANCE
[4] INST GUSTAVE ROUSSY,UNITE DIAGNOST MOLEC,F-94805 VILLEJUIF,FRANCE
[5] INT AGCY RES CANC,F-69372 LYON 08,FRANCE
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline p53 mutations have been detected in approximately half of the families affected by the Li-Fraumeni syndrome (LFS), in which they are believed to represent the genetic status predisposing to multiple cancers. Failure to detect mutations in the other half of LFS families suggests that sequence analysis, which has been limited to the p53 gene coding region, have overlooked other genetic events lying outside of this region or/and that alterations in other gene(s) than p53 may also lead to the syndrome. In this report, we present the evidence that a single base pair deletion in the p53 coding sequence, leading to premature signal termination of translation, generates a null allele by preventing transport of mutant allele mRNAs into the cytoplasm. This allelic exclusion which confers a status of unizygote vis-a-vis the wild-type p53 gene to individuals who carry the mutant allele, leads to predisposition to multiple cancers in a Li-Fraumeni family. Thus, the loss of the wild-type p53 allele appears as the rate limiting step in tumor induction.
引用
收藏
页码:2799 / 2804
页数:6
相关论文
共 50 条
  • [31] p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome
    Susan Quesnel
    Sigitas Verselis
    Carol Portwine
    Judy Garber
    Marga White
    Jean Feunteun
    David Malkin
    Frederick P Li
    Oncogene, 1999, 18 : 3970 - 3978
  • [32] Evaluation of whole body MRI for early detection of cancers in subjects with germ-line TP53 mutation (Li-Fraumeni syndrome).
    Caron, Olivier
    Frebourg, Thierry
    Bourbouloux, Emmanuelle
    Bonadona, Valerie
    Mari, Veronique
    Maugard, Christine
    Eisinger, Francois
    Barouk-Simonet, Emmanuelle
    Gauthier-Villars, Marion
    Tinat, Julie
    Nogues, Catherine
    Dugast, Catherine
    Canale, Sandra
    Guillemeau, Claire
    Benusiglio, Patrick R.
    Brugieres, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Mutant p53 regulation in a Li-Fraumeni mouse model
    Terzian, Tamara
    Plehaty, Molly
    Sobhani, Nema
    Stevens, Wanida
    Marasligiller, Stefan
    Srinivas, Tara
    Mylavarapu, Rohan
    Clarke, Yvonne
    Arbab, Farinaz
    Podell, Brendon
    Bronson, Roderick
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Novel p53 splice site mutations in three families with Li-Fraumeni syndrome
    Sigitas J Verselis
    James G Rheinwald
    Joseph F Fraumeni
    Frederick P Li
    Oncogene, 2000, 19 : 4230 - 4235
  • [35] Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations
    Gonzalez, K. D.
    Noltner, K. A.
    Buzin, C. H.
    Gu, D.
    Wen-Fong, C. Y.
    Ngyuen, V. Q.
    Han, J. H.
    Lowstuter, K.
    Longmate, J.
    Sommer, S. S.
    Weitzel, J. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome
    Fischer, Nicholas W.
    Prodeus, Aaron
    Tran, James
    Malkin, David
    Gariepy, Jean
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (12): : 1418 - 1421
  • [37] Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility
    Akashi, M
    Koeffler, HP
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1998, 41 (01): : 172 - 199
  • [38] Potential of Advexin®: a p53 gene-replacement therapy in Li-Fraumeni syndrome
    Nemunaitis, Jackie M.
    Nemunaitis, John
    FUTURE ONCOLOGY, 2008, 4 (06) : 759 - 768
  • [39] p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies
    Claudia Pötzsch
    Theda Voigtländer
    Michael Lübbert
    Journal of Cancer Research and Clinical Oncology, 2002, 128 : 456 - 460
  • [40] Germline p53 mutation in a case of Li-Fraumeni syndrome presenting gastric cancer
    Sugano, K
    Taniguchi, T
    Saeki, M
    Tsunematsu, Y
    Tomaru, U
    Shimoda, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (10) : 513 - 516